Evolocumab
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Evolocumab: From Hypercholesterolemia to Symptomatic Hemophilia in Female Carriers
One-Sentence Summary
Evolocumab is a PCSK9-inhibitor monoclonal antibody established for LDL-cholesterol lowering (its formal original-indication record is not populated in this Evidence Pack). The TxGNN model’s top prediction suggests possible relevance to symptomatic hemophilia in female carriers, but this is currently supported by 0 clinical trials and 0 publications — the prediction is model-output only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in this Evidence Pack (taiwan_regulatory.licenses is empty; original_indications is empty) |
| Predicted New Indication | Symptomatic form of hemophilia in female carriers |
| TxGNN Prediction Score | 99.82% |
| Evidence Level | L5 |
| EU Market Status | Not marketed (Not Marketed) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data for evolocumab is not available in this Evidence Pack (original_moa = Data Gap). Based on the mechanistic notes attached to this prediction, evolocumab is a PCSK9 inhibitor that acts on the LDL-receptor (LDLR) recycling pathway to lower LDL-cholesterol — a pathway with no established, direct connection to coagulation factor synthesis or clearance.
The rationale for this specific prediction explicitly flags this as a weak link: while some LDLR-family members (e.g., LRP1) participate in aspects of coagulation-factor metabolism, there is no literature support for PCSK9 inhibition affecting the hemophilia phenotype, and the direction of any effect is unclear — it could plausibly be neutral or even increase bleeding risk rather than help.
This weakness is reinforced by the broader prediction list: ranks 2–10 include several mutually contradictory disease categories (e.g., bleeding disorders like “hemorrhagic disease of newborn” alongside a pro-thrombotic condition like “inherited thrombophilia”), plus non-specific ontology labels (“disease of catalytic activity,” “disorder of other vitamins and cofactors metabolism and transport”) that are not actionable disease entities. Taken together, this pattern indicates KG-embedding similarity noise rather than a coherent, mechanistically grounded repurposing signal.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
EU Market Information
Evolocumab currently has no EU marketing authorization recorded in this dataset (market status: Not marketed / Not Marketed; 0 authorizations on file).
Safety Considerations
Please refer to the SmPC for safety information.
(Note: taiwan_regulatory marks TFDA label warnings/contraindications as a Blocking data gap (DG001) — this must be resolved via TFDA label lookup before any S1 safety evaluation can proceed.)
Conclusion and Next Steps
Decision: Hold
Rationale: The top prediction (symptomatic hemophilia in female carriers) has no supporting clinical trials or literature (L5, model prediction only), and its own mechanistic rationale describes the drug-disease link as absent or directionally uncertain. Combined with contradictory signals across the rest of the top-10 list, there is currently no basis to advance this candidate beyond a research hypothesis.
To proceed, the following is needed:
- TFDA label warnings/contraindications (blocking gap, DG001)
- Confirmed mechanism of action data via DrugBank API (DG002)
- Original indication and EU licensing records (currently empty in this pack)
- Preclinical or mechanistic studies specifically linking PCSK9/LDLR pathway activity to coagulation factor biology, if this hypothesis is to be pursued further
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.